Investment Thesis
Sunshine Biopharma is fundamentally unprofitable with negative operating and net margins (-17.2% and -16.5% respectively), burning cash at $5.5M annually in free cash flow despite modest 4.1% revenue growth. While the company maintains strong liquidity (4.17x current ratio) and low debt (0.09x debt-to-equity), it has only ~18-20 months of cash runway at current burn rates, making near-term profitability achievement critical for survival.
Strengths
- Strong short-term liquidity with 4.17x current ratio and $9.1M cash position
- Low leverage with 0.09x debt-to-equity ratio and only $7.0M total liabilities
- Reasonable gross margins at 33.8% indicating product pricing power
Risks
- Negative operating cash flow of $5.3M and negative free cash flow of $5.5M—unsustainable burn rate
- Operating and net losses despite revenue growth suggest structural unprofitability and operating expense management issues
- Limited cash runway of approximately 18-20 months at current burn rate with no clear path to profitability
- Minimal insider activity (1 Form 4 filing in 90 days) suggests low insider confidence in company direction
Key Metrics to Watch
- Operating cash flow trending—must turn positive for viability
- Revenue growth acceleration—4.1% YoY is insufficient to offset losses
- Operating expense ratio—must decline significantly to achieve profitability
- Cash burn rate and remaining runway—critical for assessing going concern risk
Financial Metrics
Revenue
36.3M
Net Income
-6.0M
EPS (Diluted)
$-0.98
Free Cash Flow
-5.5M
Total Assets
30.1M
Cash
9.1M
Profitability Ratios
Gross Margin
33.8%
Operating Margin
-17.2%
Net Margin
-16.5%
ROE
-25.9%
ROA
-19.9%
FCF Margin
-15.2%
Balance Sheet & Liquidity
Current Ratio
4.17x
Quick Ratio
2.08x
Debt/Equity
0.09x
Debt/Assets
23.4%
Interest Coverage
-126.61x
Long-term Debt
2.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-15T10:54:23.537346 |
Data as of: 2025-12-31 |
Powered by Claude AI